Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BN82451B versus placebo after oral administration twice daily (bid) for 28 days in patients with Huntington's Disease (HD).

Timeline

Start

2014-09-01

Primary completion

2016-03-31

Completion

2016-03-31

Outcome

Outcome not reported

Stopped (Enrollment): “The study was terminated due to subject recruitment problems.”

Drugs

Indications